7427 fundamentals
GNT BIOTECH & MEDICALS CORP financial statements, including revenue, expenses, and profit
The total revenue of 7427 for the last semiannual is 527.00 k TWD, and it's 498.86% higher compared to the previous semiannual. The net income of H1 24 is -61.96 M TWD.
H1 '20
H2 '20
H1 '21
H2 '21
H1 '22
H2 '22
H1 '23
H2 '23
H1 '24
−75.00 M
−50.00 M
−25.00 M
0.00
25.00 M
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: TWD
H1 '20
Jun 2020
H2 '20
Dec 2020
H1 '21
Jun 2021
H2 '21
Dec 2021
H1 '22
Jun 2022
H2 '22
Dec 2022
H1 '23
Jun 2023
H2 '23
Dec 2023
H1 '24
Jun 2024
TTM
Operating incomeYoY growth
−27.86 M
−46.10%
−37.63 M
−2.09%
−30.21 M
−8.43%
−65.06 M
−72.90%
−95.28 M
Pretax incomeYoY growth
−27.13 M
−47.19%
−35.53 M
+1.12%
−27.49 M
−1.32%
−61.96 M
−74.40%
−89.45 M
−27.13 M
−35.53 M
−27.49 M
−61.96 M
−89.45 M
Net incomeYoY growth
−27.13 M
−47.19%
−35.53 M
+1.12%
−27.49 M
−1.32%
−61.96 M
−74.40%
−89.45 M
−27.13 M
−35.53 M
−27.49 M
−61.96 M
−89.45 M
Basic earnings per share (Basic EPS)YoY growth
−0.91
−31.27%
−1.00
+26.07%
−0.69
+24.22%
−1.60
−59.97%
−2.28
Diluted earnings per share (Diluted EPS)YoY growth
−0.91
−31.27%
−1.00
+26.07%
−0.69
+24.22%
−1.60
−59.97%
−2.28
EBITDAYoY growth
−26.96 M
−47.18%
−36.47 M
−1.50%
−24.83 M
+7.90%
−61.59 M
−68.86%
−86.42 M
EBITYoY growth
−27.86 M
−46.10%
−37.63 M
−2.09%
−30.21 M
−8.43%
−65.06 M
−72.90%
−95.28 M